RESOLUTE ONYX ZOTAROLIMUS-ELUTING CORONARY STENT SYSTEM
Medtronic Vascular · Decision date Apr 28, 2017
What did the FDA approve?
FDA approved PMA P160043 for the Resolute Onyx Zotarolimus-Eluting Coronary Stent System on April 28, 2017. The applicant is Medtronic Vascular, and the product code is NIQ under the cardiovascular specialty.
The approval statement describes the device as indicated for improving coronary luminal diameters in patients, including those with diabetes mellitus, with symptomatic ischemic heart disease due to de novo lesions of length less than or equal to 35 mm in native coronary arteries with reference vessel diameters of 2.25 mm to 5.0 mm. The record does not include supplement type or supplement reason fields.
FDA approval order statement
Approval for the Resolute Onyx Zotarolimus-Eluting Coronary Stent System. This device is indicated for improving coronary luminal diameters in patients, including those with diabetes mellitus, with symptomatic ischemic heart disease due to de novo lesions of length less than or equal to 35 mm in native coronary arteries with reference vessel diameters of 2.25 mm to 5.0 mm.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Cardiovascular
- Decision date
- Apr 28, 2017
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P160043
- Regulatory pathway
- Premarket approval application
- Applicant
- Medtronic Vascular
- Product code
- NIQ
- Decision code
- APPR
- Decision date
- Apr 28, 2017
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Coronary drug-eluting stent.
- Applicant
- Medtronic Vascular
- Product code
- NIQ
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P160043 received
Application receipt date recorded by FDA.
P160043 · FDA decision
APPR
P160043/S096 · Related supplement
Resolute Onyx Zotarolimus-Eluting Coronary Stent Systems
Timeline entries are records held by MedtechLedger for P160043. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P160043
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic Vascular | PMA supplement | Oct 16, 2026 | FDA |
Explore the linked device profile
Other records with product code NIQ
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Abbott Vascular | PMA supplement | Oct 1, 2026 | FDA | |
ORSIRO Sirolimus Eluting Coronary Stent SystemP170030/S066 | Biotronik AG | PMA supplement | Sep 24, 2026 | FDA |
| Biotronik AG | PMA approval | Feb 22, 2019 | FDA | |
| Abbott Vascular | PMA approval | Nov 1, 2011 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medtronic Vascular
- Headquarters
- Not reported
- Brand website
- medtronic.com
- FDA applicant address
- 3576 Unocal Pl., Santa Rosa, CA, 95403
Sources and methodology
- Original FDA record: P160043
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



